SG11201808183PA - Methods of heat inactivation of adenovirus - Google Patents
Methods of heat inactivation of adenovirusInfo
- Publication number
- SG11201808183PA SG11201808183PA SG11201808183PA SG11201808183PA SG11201808183PA SG 11201808183P A SG11201808183P A SG 11201808183PA SG 11201808183P A SG11201808183P A SG 11201808183PA SG 11201808183P A SG11201808183P A SG 11201808183PA SG 11201808183P A SG11201808183P A SG 11201808183PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- mgc12
- methods
- particles
- aav
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101011111010111011111011111101111011111 International Bureau .. .... ..Yejd ..... .....1 (10) International Publication Number (43) International Publication Date WO 2017/172772 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) International Patent Classification: (81) Designated States (unless otherwise C12N 15/861 (2006.01) C12N 7/04 (2006.01) kind of national protection available): C12N 15/864 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, PCT/US2017/024545 HN, HR, HU, ID, IL, IN, IR, IS, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, 28 March 2017 (28.03.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, ZA, ZM, ZW. (30) Priority Data: 62/314,116 28 March 2016 (28.03.2016) US (84) Designated States (unless otherwise kind of regional protection available): (71) Applicant: DIMENSION THERAPEUTICS [US/US]; GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 TZ, UG, ZM, ZW), Eurasian (AM, (US). TJ, TM), European (AL, AT, BE, (72) Inventors: MORRISON, Christopher, J.; 118 Lowell DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Street, Arlington, MA 02474 (US). MARATT, James, D.; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 44 Lewis Road, Belmont, MA 02478 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, (74) Agents: DELFINO, Wyatt al.; Goodwin Procter LLP, et indicated, for every AE, AG, AL, AM, GD, GE, GH, GM, GT, JP, KE, KG, KH, KN, LR, LS, LU, LY, MA, PL, PT, QA, RO, RS, UG, US, UZ, VC, VN, indicated, for every ARIPO (BW, GH, AZ, BY, KG, KZ, RU, BG, CH, CY, CZ, DE, TG). 21(3)) Published: 100 Northern Avenue, Boston, MA 02210 (US). _ — — with international search report (Art. = = = = = Title: METHODS OF HEAT INACTIVATION OF ADENOVIRUS = (54) or particles, and a buffer. biological activity of The methods in - greater of divalent or = — FIG. 6 = 110% - - - - - - - - - - - - - - - -------- - ------- --- 7 - - - - - - - - - - - - = = - - - . ..__ - -,.... , .... = = .. .7 . ---- ,..„ ¨ Z - 1 -- ¨ _ - Background Buffer , 3.InsA Mg 12 Il ¨ ........ 10:riA MgC12 ¨ 5r4*1 MgC12 1 k MgC12 ei --4-- 100r0A1 Men - + -100nM MgC12 (Re aci) N O IN 50 19B 150 21q Exposure time (minutes) at 47•C 11 IN 1-1 (57) : The present disclosure generally relates to methods of protecting the genomic integrity and/or N AAV viral particles in a sample containing both AAV particles and helper virus particles during heat inactivation. dude heating, to a temperature greater than or equal to 45°C, a sample containing helper virus particles, AAV C The buffer includes a concentration of 10 mM or greater kosmotropic salts and/or a concentration of 10 mM trivalent cations.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314116P | 2016-03-28 | 2016-03-28 | |
| PCT/US2017/024545 WO2017172772A1 (en) | 2016-03-28 | 2017-03-28 | Methods of heat inactivation of adenovirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808183PA true SG11201808183PA (en) | 2018-10-30 |
Family
ID=59966403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808183PA SG11201808183PA (en) | 2016-03-28 | 2017-03-28 | Methods of heat inactivation of adenovirus |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11013774B2 (en) |
| EP (2) | EP3436593B1 (en) |
| JP (3) | JP7356224B2 (en) |
| KR (1) | KR102389674B1 (en) |
| CN (1) | CN109196106A (en) |
| AU (1) | AU2017241777B2 (en) |
| CA (1) | CA3018380A1 (en) |
| DK (1) | DK3436593T3 (en) |
| ES (1) | ES2938833T3 (en) |
| FI (1) | FI3436593T3 (en) |
| HU (1) | HUE061100T2 (en) |
| IL (1) | IL261914B2 (en) |
| LT (1) | LT3436593T (en) |
| PL (1) | PL3436593T3 (en) |
| PT (1) | PT3436593T (en) |
| SG (1) | SG11201808183PA (en) |
| WO (1) | WO2017172772A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1243922A1 (en) | 2014-11-05 | 2018-07-27 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| CA2967367C (en) | 2014-11-14 | 2023-05-16 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| US10570395B2 (en) | 2014-11-14 | 2020-02-25 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| CN117904112A (en) | 2016-05-18 | 2024-04-19 | 沃雅戈治疗公司 | Regulatory polynucleotides |
| JOP20190269A1 (en) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CN112055748A (en) * | 2018-05-11 | 2020-12-08 | 恰根有限公司 | Methods for Lysis of Plant Samples |
| BR112020023082A2 (en) | 2018-05-15 | 2021-02-09 | Voyager Therapeutics, Inc. | compositions and methods for the treatment of parkinson's disease |
| CA3114621A1 (en) | 2018-09-28 | 2020-04-02 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| WO2020132115A1 (en) | 2018-12-18 | 2020-06-25 | Ultragenyx Pharmaceutical Inc. | Methods and compositions for treating glycogen storage diseases |
| MX2021012489A (en) | 2019-04-12 | 2021-11-12 | Ultragenyx Pharmaceutical Inc | Engineered producer cell lines and methods of making and using the same. |
| JP2023031782A (en) * | 2021-08-25 | 2023-03-09 | 株式会社東芝 | Virus detection method |
| KR20240153391A (en) | 2022-03-07 | 2024-10-22 | 울트라제닉스 파마수티컬 인코포레이티드 | Modified batch AAV production system and method |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5387484A (en) | 1992-07-07 | 1995-02-07 | International Business Machines Corporation | Two-sided mask for patterning of materials with electromagnetic radiation |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| JP4216350B2 (en) * | 1994-09-19 | 2009-01-28 | 大日本住友製薬株式会社 | Recombinant DNA viral vector for animal cell infection |
| US5872005A (en) | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
| US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
| JPH10511264A (en) | 1994-12-06 | 1998-11-04 | ターゲティッド ジェネティックス コーポレイション | Packaging cell lines for the production of high titer recombinant AAV vectors |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5688676A (en) * | 1995-06-07 | 1997-11-18 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US6027931A (en) | 1995-08-03 | 2000-02-22 | Avigen, Inc. | High-efficiency AA V helper functions |
| ES2099678B1 (en) | 1995-11-03 | 1998-02-16 | Grifols Grupo Sa | PROCEDURE FOR THE INACTIVATION OF VIRUSES IN PROTEINS. |
| US6004797A (en) * | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
| WO1998027204A2 (en) | 1996-12-18 | 1998-06-25 | Targeted Genetics Corporation | Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| CA2303768C (en) | 1997-09-19 | 2009-11-24 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| IT1297074B1 (en) | 1997-11-21 | 1999-08-03 | Angeletti P Ist Richerche Bio | HORMONE-DEPENDENT FORMS OF THE REP PROTEIN OF THE ADENUS ASSOCIATED VIRUS (AAV-2), DNA SEQUENCES CODING FOR THEM, VECTORS THAT |
| AU748523B2 (en) | 1998-08-14 | 2002-06-06 | Aventis Pharmaceuticals Inc. | Adenovirus formulations for gene therapy |
| MXPA01004169A (en) | 1998-10-27 | 2002-06-04 | Crucell Holland Bv | Improved aav vector production. |
| DE19905501B4 (en) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | A method of producing a recombinant adeno-associated virus, suitable compositions therefor, and use for the manufacture of a medicament |
| CZ20013560A3 (en) * | 1999-04-09 | 2002-01-16 | Aventis Pharma S. A. | Liquid or frozen preparation intended for storing recombinant infection adenoviruses |
| US20040235173A1 (en) | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
| DE10061533B4 (en) | 2000-12-11 | 2006-05-04 | Amphenol-Tuchel Electronics Gmbh | Self-supporting contact spring, in particular for a smart card connector |
| US6492327B2 (en) * | 2000-12-19 | 2002-12-10 | Sulzer Biologics Inc. | Isolation of purified TGF- β1 and TGF -β2 from bone tissue |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| AU2002360355B2 (en) | 2001-11-09 | 2005-07-07 | Government Of The United States Of America, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| CA2369985A1 (en) | 2002-01-18 | 2003-07-18 | Duke University | Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach |
| US7622562B2 (en) * | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
| WO2004075861A2 (en) | 2003-02-26 | 2004-09-10 | Children's Hospital, Inc. | Recombinant adeno-associated virus production |
| HUE060433T2 (en) * | 2004-06-01 | 2023-03-28 | Genzyme Corp | Compositions and methods to prevent aav vector aggregation |
| US7195394B2 (en) | 2004-07-19 | 2007-03-27 | Vijay Singh | Method for resonant wave mixing in closed containers |
| US8980247B2 (en) | 2004-10-21 | 2015-03-17 | The Penn State Research Foundation | Parvovirus methods and compositions for killing neoplastic cells |
| DK1945779T3 (en) | 2005-10-20 | 2013-06-03 | Uniqure Ip Bv | Enhanced AAV vectors generated in insect cells |
| WO2007126810A2 (en) * | 2006-03-31 | 2007-11-08 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| WO2007148971A2 (en) | 2006-06-21 | 2007-12-27 | Amsterdam Molecular Therapeutics B.V. | Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells |
| GB0706638D0 (en) | 2007-04-04 | 2007-05-16 | Mbda Uk Ltd | A high-dielectric material |
| US9404150B2 (en) * | 2007-08-29 | 2016-08-02 | Sequenom, Inc. | Methods and compositions for universal size-specific PCR |
| US8580755B2 (en) | 2008-02-19 | 2013-11-12 | University Of Rochester | Methods and compositions for treating inflammatory conditions |
| US20110251547A1 (en) | 2008-11-07 | 2011-10-13 | Intelligentnano Inc. | Transfection with magnetic nanoparticles and ultrasound |
| HUE040636T2 (en) * | 2009-06-16 | 2019-03-28 | Genzyme Corp | Improved methods for purifying recombinant AAV vectors |
| US20140359799A1 (en) | 2011-12-23 | 2014-12-04 | Case Western Reserve University | Targeted gene modification using hybrid recombinant adeno-associated virus |
| EP3521420A1 (en) | 2013-01-08 | 2019-08-07 | Genzyme Corporation | Use of inos inhibitors to increase viral yield in culture |
-
2017
- 2017-03-28 SG SG11201808183PA patent/SG11201808183PA/en unknown
- 2017-03-28 DK DK17776462.8T patent/DK3436593T3/en active
- 2017-03-28 EP EP17776462.8A patent/EP3436593B1/en active Active
- 2017-03-28 EP EP22199443.7A patent/EP4159867A1/en active Pending
- 2017-03-28 JP JP2018550814A patent/JP7356224B2/en active Active
- 2017-03-28 US US16/085,177 patent/US11013774B2/en active Active
- 2017-03-28 PT PT177764628T patent/PT3436593T/en unknown
- 2017-03-28 CN CN201780033212.1A patent/CN109196106A/en active Pending
- 2017-03-28 PL PL17776462.8T patent/PL3436593T3/en unknown
- 2017-03-28 CA CA3018380A patent/CA3018380A1/en active Pending
- 2017-03-28 FI FIEP17776462.8T patent/FI3436593T3/en active
- 2017-03-28 LT LTEPPCT/US2017/024545T patent/LT3436593T/en unknown
- 2017-03-28 HU HUE17776462A patent/HUE061100T2/en unknown
- 2017-03-28 AU AU2017241777A patent/AU2017241777B2/en active Active
- 2017-03-28 WO PCT/US2017/024545 patent/WO2017172772A1/en not_active Ceased
- 2017-03-28 ES ES17776462T patent/ES2938833T3/en active Active
- 2017-03-28 KR KR1020187030706A patent/KR102389674B1/en active Active
-
2018
- 2018-09-20 IL IL261914A patent/IL261914B2/en unknown
-
2021
- 2021-02-01 JP JP2021014329A patent/JP2021072838A/en not_active Withdrawn
- 2021-04-23 US US17/238,743 patent/US11944658B2/en active Active
-
2022
- 2022-08-25 JP JP2022134006A patent/JP7682837B2/en active Active
-
2024
- 2024-02-29 US US18/591,746 patent/US20240252562A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017241777A1 (en) | 2018-10-11 |
| DK3436593T3 (en) | 2023-02-20 |
| BR112018069703A2 (en) | 2019-02-05 |
| FI3436593T3 (en) | 2023-03-16 |
| PT3436593T (en) | 2023-01-31 |
| US11944658B2 (en) | 2024-04-02 |
| AU2017241777B2 (en) | 2022-02-03 |
| CN109196106A (en) | 2019-01-11 |
| JP2022166304A (en) | 2022-11-01 |
| EP3436593B1 (en) | 2022-11-23 |
| JP2019509747A (en) | 2019-04-11 |
| IL261914B2 (en) | 2023-07-01 |
| US11013774B2 (en) | 2021-05-25 |
| ES2938833T3 (en) | 2023-04-17 |
| EP3436593A1 (en) | 2019-02-06 |
| LT3436593T (en) | 2023-03-10 |
| US20220072073A1 (en) | 2022-03-10 |
| EP3436593A4 (en) | 2019-10-16 |
| IL261914A (en) | 2018-10-31 |
| KR20180130531A (en) | 2018-12-07 |
| EP4159867A1 (en) | 2023-04-05 |
| US20240252562A1 (en) | 2024-08-01 |
| JP7682837B2 (en) | 2025-05-26 |
| PL3436593T3 (en) | 2023-03-27 |
| WO2017172772A1 (en) | 2017-10-05 |
| CA3018380A1 (en) | 2017-10-05 |
| JP2021072838A (en) | 2021-05-13 |
| IL261914B1 (en) | 2023-03-01 |
| JP7356224B2 (en) | 2023-10-04 |
| HUE061100T2 (en) | 2023-05-28 |
| KR102389674B1 (en) | 2022-04-21 |
| US20190083554A1 (en) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808183PA (en) | Methods of heat inactivation of adenovirus | |
| SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201903928WA (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201906735RA (en) | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201906765UA (en) | Personalised immunogenic peptide identification platform | |
| SG11201811435PA (en) | Automated cell processing systems and methods | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201805451TA (en) | Immune effector cell therapies with enhanced efficacy | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201807022XA (en) | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201805993UA (en) | Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein | |
| SG11201907607VA (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| SG11201810311WA (en) | Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis | |
| SG11201901620SA (en) | Methods of identifying microsatellite instability | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer |